Dash and Medicinal Genomics Beats DNA Sequencing Record of Human Genome Project

[Mark Mason]

Dash and Medicinal Genomics Beats DNA Sequencing Record of Human Genome Project

Dash’s partnership with Medicinal Genomics (MGC) continues to reap rewards by breaking DNA genome sequencing records set by the Human Genome Project in 2001.

Dash Force News caught up with Kevin McKernan, the Chief Science Officer of MGC, about their technical developments of mapping the cannabis genome. Kevin started off by highlighting how the cannabis genome is much harder to map than the Human Genome, which was the goal of the Human Genome Project in 2001. Kevin went on to discuss how Medicinal Genomics’ genome mapping has beat out the Human Genome Project that got a huge celebration and got worldwide attention at the time; he playfully hopes for similar mainstream recognition.

Read more: https://www.dashforcenews.com/dash-...na-sequencing-record-of-human-genome-project/​

 

[solarguy]

This proposal continues to bang out results that will have far reaching implications for Dash. Keep it up Kevin!

 

[Linda Butcher]

This is an awesome project. Can't wait to see how things progress.

 

[solarguy]

Kevin McKernan from Medicinal Genomics is ready to publish the cannabis genetic research funded by Dash.

This paper describes a number of "firsts".

First genetic research funded by a cryptocurrency through the Dash Treasury

First genetic data published/hashed to a blockchain to preserve and protect the data

Most complete single molecule analysis of the common cannabis genome in the world

The paper is being submitted to a number of science journals to both report on the results of the new genetic characterization of cannabis, and also to describe how the research was funded by a novel method that involved the cryptocurrency Dash.

This effort has a lot of features and benefits.

This greatly increased accuracy will assist breeders, growers, distributors, dispensaries, doctors and patients to have a greater likelihood of getting effective and inexpensive medication.

This will help the growers prove that they own and have a right to the strains they have developed for many years. It should make it more difficult for big ag and big pharma to monopolize the medical cannabis market.

This was a proof of concept that there are other ways to fund science than government or industry. Both of those methods may impose restrictions on doing the best science.

The current academic publishing industry is broken in a number of fundamental ways. This is also an ongoing effort to produce a new method of review and publishing that gives alternatives to academics that have little choice today.

There is also a big conference coming up in a week or two, where Kevin will present on the new research and Dash.

If you want to read the paper, here it is: https://osf.io/7d968/



It has a substantial section on how the Dash funding work, so not just for the geneticists out there.

 

[solarguy]

CBD and other readily accessible and inexpensive cannabis medicinals are going to change the pharmaceutical landscape in a big way. I am happy that Dash is play a not-insignificant role in that. I am no friend of big pharma, and I am a doctor......